The radiopharmaceutical industry was further consolidated last month when Schering AG’s subsidiary, Schering Berlin, announced that it has completed the purchase of 94% of the outstanding shares of peptide imaging agent developer Diatide of
The radiopharmaceutical industry was further consolidated last month when Schering AGs subsidiary, Schering Berlin, announced that it has completed the purchase of 94% of the outstanding shares of peptide imaging agent developer Diatide of Londonderry, NH. Schering Berlins tender offer, made through its subsidiary, BXA Acquisition, in September (SCAN 9/29/99), expired Oct. 22 without challenge. Schering Berlin will acquire the remaining untendered Diatide shares under another merger agreement that does not require shareholder approval. The deal is estimated at $130 million, and should be advantageous to both firms: While Diatide gains marketing and financial support, Schering gains access to Diatides R&D pipeline.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.